| scholarly article | Q13442814 |
| P356 | DOI | 10.1517/14712598.2012.681374 |
| P698 | PubMed publication ID | 22519406 |
| P50 | author | Uwe Wollina | Q49366112 |
| P2093 | author name string | Uwe Wollina | |
| P2860 | cites work | Association of cetuximab with adverse pulmonary events in cancer patients: a comprehensive review | Q21198850 |
| Radiotherapy and "new" drugs-new side effects? | Q26861498 | ||
| Association of epidermal growth factor receptor polymorphism, skin toxicity, and outcome in patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment | Q43211453 | ||
| Acute paronychia: comparative treatment with topical antibiotic alone or in combination with corticosteroid | Q43672426 | ||
| Cetuximab: an IgG(1) monoclonal antibody for the treatment of epidermal growth factor receptor-expressing tumours | Q44948356 | ||
| Oral capecitabine plus subcutaneous interferon alpha in advanced squamous cell carcinoma of the skin. | Q45201623 | ||
| Fatal diffuse alveolar damage in two lung transplant patients treated with cetuximab. | Q45997056 | ||
| Combination of an EGFR blocker and a COX-2 inhibitor for the treatment of advanced cutaneous squamous cell carcinoma | Q46166624 | ||
| Pimecrolimus: a novel treatment for cetuximab-induced papulopustular eruption | Q46365382 | ||
| Cetuximab therapy of metastasizing cutaneous squamous cell carcinoma in a patient with severe recessive dystrophic epidermolysis bullosa | Q47806783 | ||
| Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer | Q49014081 | ||
| Correlation between efficacy and skin rash occurrence following treatment with the epidermal growth factor receptor inhibitor cetuximab: a single institution retrospective analysis. | Q51768055 | ||
| Treatment of recurrent squamous cell carcinoma of the skin with cetuximab. | Q53330945 | ||
| Characterization of the expression and activation of the epidermal growth factor receptor in squamous cell carcinoma of the skin. | Q53579925 | ||
| Perifollicular xanthomas associated with epidermal growth factor receptor inhibitor therapy. | Q54691421 | ||
| Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer | Q29616236 | ||
| Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck | Q29619277 | ||
| Systematic review on infusion reactions associated with chemotherapies and monoclonal antibodies for metastatic colorectal cancer | Q31048123 | ||
| Platinum-based chemotherapy plus cetuximab in head and neck cancer | Q33381094 | ||
| Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival | Q33515519 | ||
| Clinical and economic impact of infusion reactions in patients with colorectal cancer treated with cetuximab | Q33932525 | ||
| Understanding resistance to EGFR inhibitors-impact on future treatment strategies | Q34088424 | ||
| Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck | Q34159125 | ||
| Cetuximab and radiation for primary and recurrent squamous cell carcinoma of the head and neck (SCCHN) in the elderly and multi-morbid patient: a single-centre experience | Q34408305 | ||
| Combined cetuximab and volumetric modulated arc-radiotherapy in advanced recurrent squamous cell carcinoma of the scalp | Q34413836 | ||
| Cetuximab in the treatment of head and neck cancer: preliminary results outside clinical trials | Q34417953 | ||
| Dual inhibition of epidermal growth factor receptor and insulin‐like growth factor receptor I: Reduction of angiogenesis and tumor growth in cutaneous squamous cell carcinoma | Q34442002 | ||
| Rash rates with egfr inhibitors: meta-analysis | Q34761646 | ||
| Treatment of unresectable and metastatic cutaneous squamous cell carcinoma | Q35583860 | ||
| Staphylococcus coagulase-positive skin inflammation associated with epidermal growth factor receptor-targeted therapy: an early and a late phase of papulopustular eruptions | Q35584288 | ||
| Does Sunscreen Prevent Epidermal Growth Factor Receptor (EGFR) Inhibitor–Induced Rash? Results of a Placebo-Controlled Trial from the North Central Cancer Treatment Group (N05C4) | Q35584291 | ||
| Management of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy | Q35584416 | ||
| A Japanese post-marketing surveillance of cetuximab (Erbitux®) in patients with metastatic colorectal cancer | Q35857638 | ||
| Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody | Q36094328 | ||
| Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors | Q36191575 | ||
| Surgical monotherapy versus surgery plus adjuvant radiotherapy in high-risk cutaneous squamous cell carcinoma: a systematic review of outcomes | Q37470428 | ||
| Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB). | Q37569035 | ||
| Evaluation and initial management of the patient with facial skin cancer | Q37584205 | ||
| Cetuximab-induced cutaneous toxicity | Q37635298 | ||
| The role of the hedgehog signaling pathway in the development of basal cell carcinoma and opportunities for treatment | Q37741620 | ||
| Lack of Cetuximab induced skin toxicity in a previously irradiated field: case report and review of the literature | Q37755493 | ||
| Biofilms: their role in dermal fillers | Q37770421 | ||
| Occupational ultraviolet light exposure increases the risk for the development of cutaneous squamous cell carcinoma: a systematic review and meta-analysis | Q37807451 | ||
| Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy | Q37870482 | ||
| HER2 and EGFR expression in cutaneous spindle squamous cell carcinoma | Q38428944 | ||
| Epidermal growth factor receptor inhibition augments the expression of MHC class I and II genes | Q39540889 | ||
| Recent trends in incidence of nonmelanoma skin cancers in the East of Scotland, 1992-2003. | Q40208847 | ||
| Descriptive epidemiology of basal cell carcinoma and cutaneous squamous cell carcinoma in Soria (north-eastern Spain) 1998-2000: a hospital-based survey | Q40526213 | ||
| Phase I study of anti--epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer | Q40600537 | ||
| Metastatic basal cell carcinoma: report of two cases treated with cetuximab | Q42456366 | ||
| Capecitabine for skin cancer prevention in solid organ transplant recipients | Q42479423 | ||
| Malignant melanoma and nonmelanoma skin cancers in Northrhine-Westphalia, Germany: a patient- vs. diagnosis-based incidence approach | Q42513640 | ||
| Adverse cutaneous reactions to epidermal growth factor receptor inhibitors: a study of 14 patients | Q42730853 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cetuximab | Q420296 |
| P304 | page(s) | 949-956 | |
| P577 | publication date | 2012-04-23 | |
| P1433 | published in | Expert Opinion on Biological Therapy | Q5421201 |
| P1476 | title | Cetuximab in non-melanoma skin cancer | |
| P478 | volume | 12 |
| Q58703127 | Activation and overexpression of the aryl hydrocarbon receptor contribute to cutaneous squamous cell carcinomas: an immunohistochemical study |
| Q38099285 | Advanced basal cell carcinoma. |
| Q38176823 | Aggressive behavior of cutaneous squamous cell carcinoma in patients with chronic lymphocytic leukemia |
| Q30456764 | Cetuximab for treatment of advanced squamous cell carcinoma in solid organ transplant recipients |
| Q50357203 | Chimeric Monoclonal Antibody Cetuximab Targeting Epidermal Growth Factor-Receptor in Advanced Non-Melanoma Skin Cancer |
| Q55436305 | Effective treatment of a platinum-resistant cutaneous squamous cell carcinoma case by EGFR pathway inhibition. |
| Q38448685 | Expression profiles of long noncoding RNAs in cutaneous squamous cell carcinoma |
| Q38936000 | Management of BCC and SCC of the Head and Neck |
| Q27853082 | Mutational landscape of aggressive cutaneous squamous cell carcinoma |
| Q36635998 | Recurrent squamous cell carcinoma of the skin treated successfully with single agent cetuximab therapy |
| Q38083086 | The epidermal growth factor receptor in squamous cell carcinoma: An emerging drug target |
| Q34294881 | Tomotherapy concomitant with cetuximab, followed by cetuximab as single-agent therapy for unresectable squamous cell carcinoma of the skin: a case report |
| Q38175499 | Update of cetuximab for non-melanoma skin cancer |
Search more.